Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Eirini Pectasides, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. CA Cancer J Clin. 2021 Mar; 71(2):176-190. PMID: 33165928.
    Citations: 1     Fields:    
  2. Pectasides E, Chatzidakis I, Kotoula V, Koliou GA, Papadopoulou K, Giannoulatou E, Giannouzakos VG, Bobos M, Papavasileiou C, Chrisafi S, Florou A, Pectasides D, Fountzilas G. Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. Cancer Genomics Proteomics. 2020 May-Jun; 17(3):277-290. PMID: 32345669.
    Citations:    Fields:    Translation:Humans
  3. Corso S, Isella C, Bellomo SE, Apicella M, Durando S, Migliore C, Ughetto S, D'Errico L, Menegon S, Moya-Rull D, Cargnelutti M, Capelôa T, Conticelli D, Giordano J, Venesio T, Balsamo A, Marchiò C, Degiuli M, Reddavid R, Fumagalli U, De Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molfino S, Pietrantonio F, Morano F, Siena S, Sartore-Bianchi A, Bencivenga M, Mengardo V, Rosati R, Marrelli D, Morgagni P, Rausei S, Pallabazzer G, De Simone M, Ribero D, Marsoni S, Sottile A, Medico E, Cassoni P, Sapino A, Pectasides E, Thorner AR, Nag A, Drinan SD, Wollison BM, Bass AJ, Giordano S. A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits. Cancer Res. 2019 11 15; 79(22):5884-5896. PMID: 31585941.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  4. Fountzilas E, Kotoula V, Pentheroudakis G, Manousou K, Polychronidou G, Vrettou E, Poulios C, Papadopoulou E, Raptou G, Pectasides E, Karayannopoulou G, Chrisafi S, Papakostas P, Makatsoris T, Varthalitis I, Psyrri A, Samantas E, Bobos M, Christodoulou C, Papadimitriou C, Nasioulas G, Pectasides D, Fountzilas G. Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. ESMO Open. 2019; 4(2):e000474. PMID: 31231557.
    Citations: 4     
  5. Kim ST, Banks KC, Pectasides E, Kim SY, Kim K, Lanman RB, Talasaz A, An J, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Park SH, Park JO, Park YS, Lim HY, Kim NKD, Park W, Lee H, Bass AJ, Kim K, Kang WK, Lee J. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. Ann Oncol. 2018 04 01; 29(4):1037-1048. PMID: 29409051.
    Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
  6. Pectasides E. Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time? J Thorac Dis. 2018 Mar; 10(3):1276-1279. PMID: 29707278.
    Citations: 2     
  7. Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48. PMID: 28978556.
    Citations: 64     Fields:    Translation:Humans
  8. Zhou J, Wu Z, Wong G, Pectasides E, Nagaraja A, Stachler M, Zhang H, Chen T, Zhang H, Liu JB, Xu X, Sicinska E, Sanchez-Vega F, Rustgi AK, Diehl JA, Wong KK, Bass AJ. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat Commun. 2017 01 06; 8:13897. PMID: 28059068.
    Citations: 22     Fields:    Translation:HumansAnimalsCells
  9. Johnson DB, Pectasides E, Feld E, Ye F, Zhao S, Johnpulle R, Merritt R, McDermott DF, Puzanov I, Lawrence D, Sosman JA, Buchbinder E, Sullivan RJ. Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. J Immunother. 2017 01; 40(1):31-35. PMID: 27846054.
    Citations: 28     Fields:    Translation:Humans
  10. Bockorny B, Pectasides E. The emerging role of immunotherapy in gastric and esophageal adenocarcinoma. Future Oncol. 2016 Aug; 12(15):1833-46. PMID: 27166503.
    Citations: 5     Fields:    Translation:Humans
  11. Pectasides E, Miksad R, Pyatibrat S, Srivastava A, Bullock A. Spontaneous Regression of Hepatocellular Carcinoma with Multiple Lung Metastases: A Case Report and Review of the Literature. Dig Dis Sci. 2016 09; 61(9):2749-54. PMID: 27038447.
    Citations: 7     Fields:    Translation:Humans
  12. Pectasides E. Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma. Clin Ther. 2016 Jul; 38(7):1589-99. PMID: 27041412.
    Citations: 3     Fields:    Translation:HumansCells
  13. Pectasides E, Bass AJ. ERBB2 emerges as a new target for colorectal cancer. Cancer Discov. 2015 Aug; 5(8):799-801. PMID: 26243861.
    Citations: 5     Fields:    Translation:HumansAnimals
  14. Kim J, Fox C, Peng S, Pusung M, Pectasides E, Matthee E, Hong YS, Do IG, Jang J, Thorner AR, Van Hummelen P, Rustgi AK, Wong KK, Zhou Z, Tang P, Kim KM, Lee J, Bass AJ. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest. 2014 Dec; 124(12):5145-58. PMID: 25401468.
    Citations: 31     Fields:    Translation:HumansCTClinical Trials
  15. Hong YS, Kim J, Pectasides E, Fox C, Hong SW, Ma Q, Wong GS, Peng S, Stachler MD, Thorner AR, Van Hummelen P, Bass AJ. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PLoS One. 2014; 9(10):e109440. PMID: 25350844.
    Citations: 5     Fields:    Translation:HumansCells
  16. Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Ann Oncol. 2014 Oct; 25(10):2036-2041. PMID: 25009013.
    Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
  17. Pectasides E, Rampias T, Sasaki C, Perisanidis C, Kouloulias V, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC). PLoS One. 2014; 9(4):e94273. PMID: 24722213.
    Citations: 23     Fields:    Translation:Humans
  18. Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res. 2014 Jun 01; 20(11):3023-32. PMID: 24700741.
    Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
  19. Pancoska P, Kirkwood JM, Bouros S, Spyropoulou-Vlachou M, Pectasides E, Tsoutsos D, Polyzos A, Markopoulos C, Panagiotou P, Castana O, Bafaloukos D, Fountzilas G, Gogas H. A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. PLoS One. 2014; 9(1):e86375. PMID: 24475110.
    Citations:    Fields:    Translation:Humans
  20. Peterson EA, Pectasides E, Shabbeer S, Wiechmann L, Sparano JA, Kenny PA. Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls. Exp Hematol Oncol. 2013 Sep 08; 2(1):25. PMID: 24010672.
    Citations: 2     
  21. Rampias T, Pectasides E, Prasad M, Sasaki C, Gouveris P, Dimou A, Kountourakis P, Perisanidis C, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype. Ann Oncol. 2013 Aug; 24(8):2124-31. PMID: 23406730.
    Citations: 11     Fields:    Translation:HumansCells
  22. Husain H, Psyrri A, Markovic A, Rampias T, Pectasides E, Wang H, Slebos R, Yarbrough WG, Burtness B, Chung CH. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope. 2012 Dec; 122(12):2762-8. PMID: 23086695.
    Citations: 5     Fields:    Translation:HumansCells
  23. Mountzios G, Soultati A, Pectasides D, Pectasides E, Dimopoulos MA, Papadimitriou CA. Developments in the systemic treatment of metastatic cervical cancer. Cancer Treat Rev. 2013 Aug; 39(5):430-43. PMID: 22727690.
    Citations: 13     Fields:    Translation:Humans
  24. Psyrri A, Ghebremichael MS, Pectasides E, Dimou AT, Burtness B, Rimm D, Wanebo HJ, Forastiere AA. p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2011 May 20; 29(15_suppl):e16032. PMID: 28023645.
  25. Bai Y, Tolles J, Cheng H, Siddiqui S, Gopinath A, Pectasides E, Camp RL, Rimm DL, Molinaro AM. Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab Invest. 2011 Aug; 91(8):1253-61. PMID: 21519325.
    Citations: 24     Fields:    Translation:Humans
  26. Pectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, Zaramboukas T, Rimm D, Burtness B, Psyrri A. Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clin Cancer Res. 2011 May 01; 17(9):2947-54. PMID: 21355076.
    Citations: 15     Fields:    Translation:Humans
  27. Gogas H, Dafni U, Koon H, Spyropoulou-Vlachou M, Metaxas Y, Buchbinder E, Pectasides E, Tsoutsos D, Polyzos A, Stratigos A, Markopoulos C, Panagiotou P, Fountzilas G, Castana O, Skarlos P, Atkins MB, Kirkwood JM. Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med. 2010 Nov 03; 8:108. PMID: 21044351.
    Citations: 7     Fields:    Translation:HumansCells
  28. Mountzios G, Pectasides D, Bournakis E, Pectasides E, Bozas G, Dimopoulos MA, Papadimitriou CA. Developments in the systemic treatment of endometrial cancer. Crit Rev Oncol Hematol. 2011 Sep; 79(3):278-92. PMID: 20833559.
    Citations: 5     Fields:    Translation:Humans
  29. Pectasides D, Pectasides E, Papaxoinis G, Psyrri A, Pliarchopoulou K, Koumarianou A, Macheras A, Athanasas G, Xiros N, Economopoulos T. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma. Gynecol Oncol. 2010 Jul; 118(1):52-7. PMID: 20406710.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  30. Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A. Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res. 2010 Apr 15; 16(8):2427-34. PMID: 20371693.
    Citations: 29     Fields:    Translation:HumansCells
  31. Rampias T, Boutati E, Pectasides E, Sasaki C, Kountourakis P, Weinberger P, Psyrri A. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res. 2010 Mar; 8(3):433-43. PMID: 20215420.
    Citations: 38     Fields:    Translation:HumansCells
  32. Pectasides D, Pectasides E, Papaxoinis G, Andreadis C, Papatsibas G, Fountzilas G, Pliarchopoulou K, Macheras A, Aravantinos G, Economopoulos T. Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. Gynecol Oncol. 2009 Oct; 115(1):97-101. PMID: 19615725.
    Citations: 11     Fields:    Translation:Humans
  33. Psyrri D, Pectasides E, Weinberger P, Sasaki C, Burtness B, Fountzilas G. Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype. J Clin Oncol. 2009 May 20; 27(15_suppl):6031. PMID: 27962428.
  34. Pectasides E, Founztilas G, Sasaki C, Burtness B, Psyrri A. Assessment of phosphatidylinositol-3 kinase (PI3K) as a prognostic marker in head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2009 May 20; 27(15_suppl):e17028. PMID: 27961677.
  35. Pectasides D, Fountzilas G, Papaxoinis G, Pectasides E, Xiros N, Sykiotis C, Koumarianou A, Psyrri A, Panayiotides J, Economopoulos T. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer. Int J Gynecol Cancer. 2009 May; 19(4):777-81. PMID: 19509587.
    Citations: 8     Fields:    Translation:Humans
  36. Pectasides D, Papaxoinis G, Nikolaou M, Valavanis C, Aravantinos G, Fountzilas G, Tamvakis N, Pectasides E, Lekka I, Arapantoni-Dadioti P, Zizi A, Ghiconti I, Economopoulos T. Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1. Anticancer Res. 2009 Feb; 29(2):737-44. PMID: 19331230.
    Citations: 3     Fields:    Translation:Humans
  37. Pectasides D, Pectasides E, Papaxoinis G, Koumarianou A, Psyrri A, Xiros N, Tountas N, Kamposioras K, Papatsibas G, Floros T, Gouveris P, Karageorgopoulou S, Economopoulos T. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience. Anticancer Res. 2009 Feb; 29(2):769-75. PMID: 19331234.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  38. Pectasides D, Pectasides E, Papaxoinis G, Skondra M, Gerostathou M, Karageorgopoulou S, Kamposioras C, Tountas N, Koumarianou A, Psyrri A, Macheras A, Economopoulos T. Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy. J Androl. 2009 May-Jun; 30(3):280-6. PMID: 19136393.
    Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
  39. Pectasides D, Pectasides E, Papaxoinis G, Xiros N, Kamposioras K, Tountas N, Economopoulos T. Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors. Urol Oncol. 2010 Nov-Dec; 28(6):617-23. PMID: 19110454.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  40. Pectasides D, Pectasides E, Constantinidou A, Aravantinos G. Stage I testicular seminoma: management and controversies. Crit Rev Oncol Hematol. 2009 Jul; 71(1):22-8. PMID: 19046898.
    Citations: 7     Fields:    Translation:Humans
  41. Pectasides D, Pectasides E, Constantinidou A, Aravantinos G. Current management of stage I testicular non-seminomatous germ cell tumours. Crit Rev Oncol Hematol. 2009 May; 70(2):114-23. PMID: 18805019.
    Citations: 3     Fields:    Translation:Humans
  42. Pectasides D, Iacovidou I, Psyrri A, Gaglia A, Pectasides E, Papaxoinis G, Drakou A, Xiros N, Economopoulos T. Primary ovarian lymphoma: report of two cases and review of the literature. J Chemother. 2008 Aug; 20(4):513-7. PMID: 18676235.
    Citations: 1     Fields:    Translation:Humans
  43. Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Chemotherapy for recurrent cervical cancer. Cancer Treat Rev. 2008 Nov; 34(7):603-13. PMID: 18657909.
    Citations: 32     Fields:    Translation:Humans
  44. Pectasides D, Pectasides E, Papaxoinis G, Xiros N, Sykiotis C, Papachristodoulou A, Tountas N, Panayiotides J, Economopoulos T. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution. Gynecol Oncol. 2008 Sep; 110(3):299-303. PMID: 18602677.
    Citations: 8     Fields:    Translation:Humans
  45. Pectasides D, Nikolaou M, Pectasides E, Koumarianou A, Valavanis C, Economopoulos T. Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma. Anticancer Res. 2008 Jul-Aug; 28(4C):2317-20. PMID: 18751412.
    Citations: 8     Fields:    Translation:Humans
  46. Pectasides E, Kountourakis P, Fountzilas G, Burtness BA, Psyrri A. Evaluation of the prognostic significance of activated STAT3 expression levels in head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2008 May 20; 26(15_suppl):6015. PMID: 27950652.
  47. Gogas H, Metaxas Y, Dafni U, Polyzos A, Fountzilas G, Pectasides E, Skarlos D, Tsoutsos D, Panagiotou P, Spyropoulou-Vlachou M. Evaluation of CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. J Clin Oncol. 2008 May 20; 26(15_suppl):9054. PMID: 27950736.
  48. Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. Cancer Treat Rev. 2008 Aug; 34(5):427-41. PMID: 18378402.
    Citations: 28     Fields:    Translation:Humans
  49. Pectasides D, Iacovidou I, Psyrri A, Pectasides E, Papaxoinis G, Economopoulos T. Primary non-Hodgkin's lymphoma of the bladder: report of two cases and review of the literature. J BUON. 2008 Apr-Jun; 13(2):277-9. PMID: 18555478.
    Citations:    Fields:    Translation:Humans
  50. Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, Psyrri A, Gaglia A, Kassanos D, Gouveris P, Panayiotidis J, Fountzilas G, Economopoulos T. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol. 2008 May; 109(2):250-4. PMID: 18299146.
    Citations: 8     Fields:    Translation:Humans
  51. Pectasides D, Papaxoinis G, Fountzilas G, Aravantinos G, Pectasides E, Mouratidou D, Economopoulos T, Andreadis Ch. Adult granulosa cell tumors of the ovary: a clinicopathological study of 34 patients by the Hellenic Cooperative Oncology Group (HeCOG). Anticancer Res. 2008 Mar-Apr; 28(2B):1421-7. PMID: 18505090.
    Citations: 8     Fields:    Translation:Humans
  52. Pectasides D, Papaxoinis G, Pectasides E, Galani H, Razi E, Katodrytis N, Fountzilas G, Economopoulos T. Merkel cell carcinoma of the skin: a retrospective study of 24 cases by the Hellenic Cooperative Oncology Group. Oncology. 2007; 72(3-4):211-8. PMID: 18176086.
    Citations: 3     Fields:    Translation:Humans
  53. Pectasides D, Xiros N, Papaxoinis G, Aravantinos G, Sykiotis C, Pectasides E, Psyrri A, Koumarianou A, Gaglia A, Gouveris P, Economopoulos T. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma. Gynecol Oncol. 2008 Jan; 108(1):47-52. PMID: 17915300.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  54. Pectasides D, Pectasides E, Psyrri A. Granulosa cell tumor of the ovary. Cancer Treat Rev. 2008 Feb; 34(1):1-12. PMID: 17945423.
    Citations: 35     Fields:    Translation:Humans
  55. Gaglia A, Bobota A, Pectasides E, Kosmas C, Papaxoinis G, Pectasides D. Successful treatment with cyclosporine of thymoma-related aplastic anemia. Anticancer Res. 2007 Jul-Aug; 27(4C):3025-8. PMID: 17695491.
    Citations: 5     Fields:    Translation:Humans
  56. Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev. 2007 Apr; 33(2):177-90. PMID: 17196749.
    Citations: 17     Fields:    Translation:Humans
  57. Pectasides D, Pectasides E. Maintenance or consolidation therapy in advanced ovarian cancer. Oncology. 2006; 70(5):315-24. PMID: 17164587.
    Citations: 5     Fields:    Translation:Humans
  58. Pectasides D, Pectasides M, Psyrri A, Koumarianou A, Xiros N, Pectasides E, Gaglia A, Lianos E, Papaxoinis G, Lampadiari V, Economopoulos T. Cisplatin-based chemotherapy for merkel cell carcinoma of the skin. Cancer Invest. 2006 Dec; 24(8):780-5. PMID: 17162559.
    Citations: 10     Fields:    Translation:Humans
  59. Pectasides D, Pectasides E, Psyrri A, Economopoulos T. Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist. 2006 Nov-Dec; 11(10):1089-94. PMID: 17110628.
    Citations: 33     Fields:    Translation:Humans
  60. Pectasides D, Pectasides E, Economopoulos T. Fallopian tube carcinoma: a review. Oncologist. 2006 Sep; 11(8):902-12. PMID: 16951394.
    Citations: 35     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Pectasides's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (239)
Co-Authors (15)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.